NCT03827941 Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism
| NCT ID | NCT03827941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-11-01 |
| Primary Completion | 2027-09-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-11-01 with a primary completion date of 2027-09-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, investigators will examine the treatment effects of transcutaneous electrical nerve stimulation with different stimulation frequencies on individuals with autism.
Eligibility Criteria
Inclusion Criteria: 1. Autism diagnosed based on DSM-V classification criteria 2. 18-60 year old high functioning adult autism patients (e.g. Asperger's, IQ equal or greater than 80) 3. Subjects who do not show aggressive behaviors based on neuro/psychiatric evaluations as determined by a licensed study physician. Exclusion Criteria: 1. A history of chronic serious infection, any current infection, any type of cancer or autoimmune disease or other severe diseases; 2. Subjects taking any medications that confound the study results
Contact & Investigator
Jian Kong
PRINCIPAL INVESTIGATOR
MGH
Frequently Asked Questions
Who can join the NCT03827941 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03827941 currently recruiting?
Yes, NCT03827941 is actively recruiting participants. Contact the research team at sahodges@mgb.org for enrollment information.
Where is the NCT03827941 trial being conducted?
This trial is being conducted at Charlestown, United States.
Who is sponsoring the NCT03827941 clinical trial?
NCT03827941 is sponsored by Massachusetts General Hospital. The principal investigator is Jian Kong at MGH. The trial plans to enroll 40 participants.